文献速递泌尿生殖与妇科肿瘤放疗

中高危前列腺癌大分割高剂量调强放疗后患者报告毒性与生活质量

Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-05-21

该研究纳入462例中高危局限期前列腺癌患者,采用70 Gy/28次(2.5 Gy/次)IMRT/VMAT联合基准标记在线校正与每日直肠气囊,3年与5年无失败生存率分别为92.0%与83.5%。患病率比 actuarial 发生率与HRQoL相关性更好。

要点

  • 70 Gy/28次大分割IMRT/VMAT方案5年无失败生存率83.5%。
  • 患病率比 actuarial 发生率更能反映毒性负担与HRQoL。

核心结论

  • 中高危局限期前列腺癌采用70 Gy/28次IMRT/VMAT联合基准标记与直肠气囊,可获得良好长期肿瘤控制与可接受的患者报告毒性。

研究设计与样本

  • 2008至2016年间462例中高危局限期前列腺癌患者接受28次2.5 Gy(总70 Gy)IMRT/VMAT,采用基准标记在线校正协议与每日插入直肠气囊。

主要发现

  • 3年与5年总体无失败率分别为92.0%(89.1-94.9%)与83.5%(78.6-88.4%)。
  • 5年≥2级泌尿/胃肠毒性 actuarial 发生率分别为43.5%/18.5%。
  • HRQoL在放疗期间恶化,此后逐渐恢复,与患病率变化一致。

关键数值与推荐

  • 放疗剂量方案为70 Gy分28次,每次2.5 Gy。

临床怎么用

  • 该大分割方案可作为中高危局限期前列腺癌的放疗选择之一,需配合基准标记在线校正与直肠气囊。
  • 患者报告结局(含HRQoL)应纳入疗效与毒性评估,患病率比 actuarial 发生率更能反映毒性负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: For irradiation of localized prostate-cancer, moderately-hypofractionated regimens with a variety of dose per fraction are used. We adopted a regimen of 70 Gy in 28 fractions of 2.5 Gy, using state of the art radiotherapy (RT) and closely monitored the efficacy, toxicity and health-related quality of life (HRQoL) in a large cohort, using patient-reported outcomes. MATERIALS AND METHODS: Between 2008 and 2016, 462 patients with intermediate- to high-risk localized prostate cancer were treated with RT, 28 fractions of 2.5 Gy, using IMRT/VMAT, an online fiducial-maker based correction protocol and a daily inserted endorectal balloon. Overall freedom from failure (no biochemical or clinical recurrence) , as well as self-reported genitourinary (GU) and gastrointestinal (GI) related toxicity and HRQoL are reported. RESULTS: Overall freedom from failure rates at 3 and 5 years were 92.0% (89.1-94.9%) and 83.5% (78.6-88.4%), respectively. Prevalence rates of grade ≥ 2 GU/GI-toxicity were 16.3%/6.3% and 22,1%/3.2% after 3 and 5 years respectively. The 5-year actuarial incidences of grade ≥ 2 GU/GI-toxicity were 43.5%/18.5%. HRQoL worsened during RT and gradually recovered thereafter, In accordance with the prevalence rates. CONCLUSION: Treatment of intermediate- or high-risk localized prostate cancer with RT to 70 Gy in 28 fractions with IMRT/VMAT, using fiducial markers and an endorectal balloon leads to good long-term tumor control rates and acceptable patient reported toxicity rates. Furthermore, patient-reported outcomes, including HRQoL, are essential for a good comparison between different studies. Finally, prevalence rates show a better correlation with HRQoL than actuarial incidence rates do and might therefore better represent the burden of toxicity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Houben J, McColl G, Ham Kaanders J, et al. Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer. Clin Transl Radiat Oncol. 2021. PMID: 34113724. doi:10.1016/j.ctro.2021.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。